Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either confirmed through a tissue sample or through standard clinical diagnosis methods
• People whose liver cancer has spread outside the liver (metastases) and cannot be removed with surgery, as confirmed by imaging scans
• People who have not previously been treated with a PD-L1 antibody medicine or bevacizumab (specific types of cancer treatments)
• People aged 18 to 75 years
• People with a general health and activity level rated as 0 or 1 on a standard medical scale, meaning they are fully active or have only minor limitations in physical activity
• People with liver function rated as Child-Pugh Class A or B7 (a standard measure of how well the liver is working)
• People who are willing and able to follow all the requirements of the study
• People who have at least one measurable or assessable area of cancer visible on scans, according to standard measurement guidelines
• People whose blood counts and organ function meet minimum levels, including sufficient white blood cells, platelets, haemoglobin, and acceptable kidney, liver, and thyroid function (confirm specific values with trial site)
• People with a life expectancy of at least 12 weeks
• People of childbearing potential who are willing to use effective contraception during treatment and for 6 months after the last dose

Who may not be able to join:

• People who have serious complications from liver disease, such as severe bleeding, active infection, or confusion caused by liver failure
• People who have previously had any systemic (whole-body) treatment for their liver cancer
• People who have had another cancer within the past 5 years, except for certain treated skin cancers or early-stage cancers that have been fully treated
• People who are currently taking part in another interventional clinical trial
• People who have used Chinese herbal medicine or immune-modifying treatments within 2 weeks before the first dose
• People who have an active autoimmune disease that has required systemic treatment within the past 2 years
• People who have used systemic corticosteroid medicines (such as prednisone) within 7 days before the first dose
• People who have previously had an organ transplant (other than a cornea transplant) or a stem cell transplant
• People with a known allergy to monoclonal antibody medicines or to any components used in the treatment being studied
• People who have not sufficiently recovered from side effects of previous treatments
• People with a known HIV infection
• People with an untreated active hepatitis B infection (confirmed by specific blood test results)
• People with an active hepatitis C infection
• People who have received a live vaccine within 30 days before the first dose
• People who are pregnant or breastfeeding
• People with serious or uncontrolled health conditions, including certain heart problems, uncontrolled high blood pressure, a blood clot or arterial event in the past 6 months, active lung disease, active tuberculosis, active serious infections, uncontrolled diabetes, significant kidney protein leakage, psychiatric conditions that may affect participation, or any other condition that could interfere with the study (confirm specific conditions with trial site)

Important: Always verify eligibility with the trial site directly before applying.